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     Despite the current availability of a plethora of treatment modalities, substitutes, and various clinical 
adjuncts, autogenous tissue replacement are still the gold standard to which all other reconstructive 
procedures are compared. However, autogenous grafts have several significant limitations, namely the 
availability of competent sites and inherent donor site morbidity.In oral and maxillofacial area, skin, 
muscles, bones , tendon, mucosa and  teeth made reconstruction efforts very complicated to reach to the 
optimum point of function, aesthetic and mastication.  
The traditional triad of tissue engineering attempts to replicate the intrinsic properties of autograft 
reconstructions.This triad consists of sufficient competent cell transfer, structured scaffolding that 
maintains space and provides conduction, and the application of miscellaneous growth factors that can 
further induce adjacent mesenchymal osteogenesis. The added major advantage of tissue engineering 
over autogenous grafting is that engineered tissue is produced in an ex vivo context that avoids the 
drawbacks of autograft donor morbidity and availability. 
Current researchers continue to concentrate on promoting the tissue-engineering model as the new “state 
of the art” in dentistry. Jaw bones, oral mucosa and teeth are the main target for either regenerative 
medicine or tissue engineering in this area.   
Several clinical conditions such as trauma, tumor resection and congenital malformations are 
characterized by a loss/lack of bone tissue which necessitates intervention to promote repair. Despite 
many advances in tissueengineering, an exact reconstructive recapitulation of large defects continues to 
be beyond reach. Till today for the critical sized defects there is no general consensus that regenerative 
methods could be an appropriate replacement for autogenous tissue transfer. For edentulism, the standard 
treatment is still the use of dental implants. Moreover, physiologic atrophy of alveolar ridges following 
tooth extraction might necessitate a bone augmentation procedure for dental implant treatments to 
become feasible. In non-critical sized defects the scenario was somehow different and cell based 
approaches showed satisfactory results. Bone marrow mesenchymal stem cells seeded on biphasic 
hydroxyapatite-tricalcium phosphate used in treatment of posterior maxillary atrophy and sinus floor 
augmentation. Alveolar clefts patients also benefitted from the use cell therapy .we treated more than 10 
patients by delivering stem cells to the cleft defects. Mesenchymal stem cells also resulted in 
enhancement of osseointegration around dental implants.
 
Recently dental pulp can serve as a good 
source for harvesting and culturing mesenchymal stem cells and is going to the main source in 
dentomaxillofacial regeneration. In future by using bioreactors, enhancement of cell delivery methods, 
co culturing of cells, gradual concomitant release of growth factors during cell seeding and recipient site 
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